D-Dimer Efficacy Evaluated for Disseminated Intravascular Coagulation Diagnosis
|
By LabMedica International staff writers Posted on 17 Feb 2016 |

Image: Sysmex C-1500 automatic coagulation analyzer (Photo courtesy of Siemens Healthcare).

Image: The Innovance D-Dimer reagent set (Photo courtesy of Siemens Healthcare).
Disseminated intravascular coagulation refers to an acquired syndrome characterized by procoagulant substances entering the general circulation and leading to a systemic thrombotic process, which may be derived from or causing microvascular system damage.
D-dimer (D-D) was shown to be an important indicator for the diagnosis of overt disseminated intravascular coagulation (DIC) and non-overt DIC; however, its diagnostic cutoff value in the clinic is not clearly defined. The initiation of treatment in nonovert DIC leads to better outcome than in DIC and therefore, early diagnosis of non-overt DIC is pivotal for DIC prevention and treatment.
Clinical scientists at the Nanjing Medical University (Suzhou, China) enrolled 40 male and 80 female cases in each group (DIC, non-overt DIC, and non-DIC control group). All 360 cases were collected in Suzhou Municipal Hospital. The DIC group included patients clearly diagnosed with DIC who had been hospitalized in the intensive care unit (ICU); the non-overt DIC group comprised patients who were diagnosed later as DIC; and the non-DIC control group included patients who were convalescing after surgery, had normal liver and kidney function.
D-D, fibrinogen degradation products (FDP), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fg), thrombin time (TT), antithrombin (AT), and blood platelet count (PLT) of 360 cases were used to assess the diagnostic efficacy of Innovance D-Dimer reagent (Siemens Healthcare Diagnostics, Erlangen, Germany) for the diagnosis of DIC and non-overt DIC, compared to, or combined with, other DIC coagulation indicators. D-D was quantitatively analyzed using a Sysmex CA1500 automatic coagulation analyzer (Sysmex Corporation; Kobe, Japan) with an immunoturbidimetric method.
The investigators found that when D-D was greater than 3.0 μg/mL was used as the cutoff, the sum of diagnostic sensitivity and specificity reached maximum values for DIC and non-overt DIC, whereas the sum of misdiagnoses and missed diagnosis rate was minimal. Excluding D-D, AT, or Fg, but not TT, from the test combination reduced the diagnostic sensitivity of DIC or non-overt DIC by various degrees. Combining two factors, D-D of greater than 3.0 μg/mL and FDP of greater than 10 mg/L, increased the sensitivity and specificity for the diagnosis of DIC and non-overt DIC.
The authors concluded that monitoring D-D and FDP levels is useful for early intervention and improving microcirculation disturbance caused by disease. They propose that a cutoff value of D-D of greater than 3.0 μg/mL would be suitable for the InnovanceR D-D reagent in the laboratory; D-D in combination with FDP is meaningful for primary screening of non-overt DIC. The study was published on February 2, 2016, in the International Journal of Laboratory Hematology.
Related Links:
Nanjing Medical University
Siemens Healthcare Diagnostics
Sysmex Corporation
D-dimer (D-D) was shown to be an important indicator for the diagnosis of overt disseminated intravascular coagulation (DIC) and non-overt DIC; however, its diagnostic cutoff value in the clinic is not clearly defined. The initiation of treatment in nonovert DIC leads to better outcome than in DIC and therefore, early diagnosis of non-overt DIC is pivotal for DIC prevention and treatment.
Clinical scientists at the Nanjing Medical University (Suzhou, China) enrolled 40 male and 80 female cases in each group (DIC, non-overt DIC, and non-DIC control group). All 360 cases were collected in Suzhou Municipal Hospital. The DIC group included patients clearly diagnosed with DIC who had been hospitalized in the intensive care unit (ICU); the non-overt DIC group comprised patients who were diagnosed later as DIC; and the non-DIC control group included patients who were convalescing after surgery, had normal liver and kidney function.
D-D, fibrinogen degradation products (FDP), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fg), thrombin time (TT), antithrombin (AT), and blood platelet count (PLT) of 360 cases were used to assess the diagnostic efficacy of Innovance D-Dimer reagent (Siemens Healthcare Diagnostics, Erlangen, Germany) for the diagnosis of DIC and non-overt DIC, compared to, or combined with, other DIC coagulation indicators. D-D was quantitatively analyzed using a Sysmex CA1500 automatic coagulation analyzer (Sysmex Corporation; Kobe, Japan) with an immunoturbidimetric method.
The investigators found that when D-D was greater than 3.0 μg/mL was used as the cutoff, the sum of diagnostic sensitivity and specificity reached maximum values for DIC and non-overt DIC, whereas the sum of misdiagnoses and missed diagnosis rate was minimal. Excluding D-D, AT, or Fg, but not TT, from the test combination reduced the diagnostic sensitivity of DIC or non-overt DIC by various degrees. Combining two factors, D-D of greater than 3.0 μg/mL and FDP of greater than 10 mg/L, increased the sensitivity and specificity for the diagnosis of DIC and non-overt DIC.
The authors concluded that monitoring D-D and FDP levels is useful for early intervention and improving microcirculation disturbance caused by disease. They propose that a cutoff value of D-D of greater than 3.0 μg/mL would be suitable for the InnovanceR D-D reagent in the laboratory; D-D in combination with FDP is meaningful for primary screening of non-overt DIC. The study was published on February 2, 2016, in the International Journal of Laboratory Hematology.
Related Links:
Nanjing Medical University
Siemens Healthcare Diagnostics
Sysmex Corporation
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







